Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine.
COVID-19
HLA
antibody
mRNA vaccine
spike protein
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
05
01
2022
received:
19
08
2021
accepted:
07
01
2022
pubmed:
14
1
2022
medline:
19
2
2022
entrez:
13
1
2022
Statut:
ppublish
Résumé
The polymorphism of the HLA system has been extensively studied in COVID-19 infection, however there are no data about the role of HLA on vaccine response. We report here the HLA-A, -B, -C, and DRB1 allelic frequencies of n = 111 individuals after BNT162b2 mRNA vaccine, selected on the basis of lower antibody levels (<5% percentile) after the second dose among a total of n = 2569 vaccinees, and compare them with the frequencies of a reference population. We found that differences in the frequencies of the alleles HLA-A*03:01, A*33:03, B*58:01 and at least one haplotype (HLA-A*24:02~C*07:01~B*18:01~DRB1*11:04) are associated with a weaker antibody response after vaccination, together with the age of vaccinees. Our results might suggest a role played by some HLA alleles or haplotypes in antibody production after the BNT162b2 mRNA vaccine, giving insights into the tracking of potentially susceptible individuals across populations. Further studies are needed to better define our exploratory findings and dissect the role of HLA polymorphism on response to anti-COVID-19 vaccines.
Substances chimiques
Antibodies, Viral
0
HLA-DRB1 Chains
0
Vaccines, Synthetic
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-191Subventions
Organisme : Servizio di Immunoematologia e Medicina Trasfusionale of the ASST Grande Ospedale Metropolitano Niguarda.
Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. Vaccine. 2012;30:4414-4418.
Kallen K-J, Theß A. A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines. 2014;2:10-31.
Novelli A, Andreani M, Biancolella M, et al. HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. HLA. 2020;96:610-614.
Anzurez A, Naka I, Miki S, et al. Association of HLA-DRB1*09:01 with severe COVID-19. HLA. 2021;98:37-42.
Langton DJ, Bourke SC, Lie BA, et al. The influence of HLA genotype on the severity of COVID-19 infection. HLA. 2021;98:14-22.
Ben Shachar S, Barda N, Manor S, et al. MHC Haplotyping of SARS-CoV-2 patients: HLA subtypes are not associated with the presence and severity of COVID-19 in the Israeli population. J Clin Immunol. 2021;41:1154-1161.
Pisanti S, Deelen J, Gallina AM, et al. Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19. J Transl Med. 2020;18:352.
Yung Y-L, Cheng C-K, Chan H-Y, et al. Association of HLA-B22 serotype with SARS-CoV-2 susceptibility in Hong Kong Chinese patients. HLA. 2021;97:127-132.
Augusto DG, Yusufali T, Peyser ND, et al. HLA-B*15:01 is associated with asymptomatic SARS-CoV-2 infection. medRxiv. 2021. doi:10.1101/2021.05.13.21257065
Pretti MAM, Galvani RG, Vieira GF, et al. Class I HLA allele predicted restricted antigenic coverages for spike and nucleocapsid proteins are associated with deaths related to COVID-19. Front Immunol. 2020;11:565730.
Nguyen A, David JK, Maden SK, et al. HLA susceptibility map for severe acute respiratory syndrome coronavirus 2. J Virol. 2020;94:e00510-20.
Barquera R, Collen E, Di D, et al. Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide. HLA. 2020;96:277-298.
Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020;383:1522-1534.
Littera R, Campagna M, Deidda S, et al. HLA complex and other Immunogenetic and clinical factors influence susceptibility or protection to SARS-CoV-2 infection and severity of the disease course. The Sardinian Experience. Front Immunol. 2020;11:605688.
Amoroso A, Magistroni P, Vespasiano F, et al. HLA and AB0 polymorphisms may influence SARS-CoV-2 infection and COVID-19 severity. Transplantation. 2021;105:193-200.
Mitsunaga T, Ohtaki Y, Seki Y, et al. The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan. medRxiv. 2021. doi:10.1101/2021.07.18.21260579
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-2615.
Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. 2020;586:594-599.
Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383:2439-2450.
Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39:4423-4428.
Zhou Z-H, Dharmarajan S, Lehtimaki M, Kirshner SL, Kozlowski S. Early antibody responses associated with survival in COVID19 patients. PLoS Pathog. 2021;17:e1009766.
Sacchi N, Castagnetta M, Miotti V, Garbarino L, Gallina A. High-resolution analysis of the HLA-A, -B, -C and -DRB1 alleles and national and regional haplotype frequencies based on 120 926 volunteers from the Italian bone marrow donor registry. HLA. 2019;94:285-295.
Cereb N, Kim HR, Ryu J, Yang SY. Advances in DNA sequencing technologies for high resolution HLA typing. Hum Immunol. 2015;76:923-927.
Nishida N, Sugiyama M, Sawai H, et al. Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. Hepatology. 2018;68:848-858.
Requena D, Médico A, Chacón RD, Ramírez M, Marín-Sánchez O. Identification of novel candidate epitopes on SARS-CoV-2 proteins for South America: a review of HLA frequencies by country. Front Immunol. 2020;11:2008.